Skip to content

Study · Randomized controlled trial · n = 47 · 2020

9 results

Effect of Liraglutide on Cardiovascular Function and Myocardial Tissue Characteristics in Type 2 Diabetes Patients of South Asian Descent Living in the Netherlands: A Double-Blind, Randomized, Placebo-Controlled Trial.

Paiman EHM, van Eyk HJ, van Aalst MMA, Bizino MB, van der Geest RJ, Westenberg JJM, Geelhoed-Duijvestijn PH, Kharagjitsingh AV, Rensen PCN, Smit JWA, Jazet IM, Lamb HJ

Journal of magnetic resonance imaging : JMRI4 Dec 2019Cited by 32 (Europe PMC)

PMID31799782 (opens in a new tab)PMCIDPMC7318583 (opens in a new tab)DOI10.1002/jmri.27009 (opens in a new tab)PepBankPUB-31799782
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In South Asian adults with type 2 diabetes, liraglutide did not change the left ventricular early deceleration peak compared with placebo.

    In plain wordsIn South Asian adults with type 2 diabetes, liraglutide did not change heart filling speed compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeEarly deceleration peak (Edec)
    Study

    n = 47

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg/day · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Liraglutide (n = 22) compared with placebo (n = 25) did not change Edec (+0.2 mL/s2 × 10-3 (-0.3;0.6)), E/A (-0.09 (-0.23;0.05)), E/Ea (+0.1 (-1.2;1.3)) and ejection fraction (0% (-3;2)), but decreased stroke volume (-9 mL (-14;-5)) and increased heart rate (+10 bpm (4;15)).
    2 context sentences
    Summary · context
    Primary endpoints were changes in LV diastolic function (early deceleration peak [Edec], ratio of early and late peak filling rate [E/A], estimated LV filling pressure [E/Ea]) and LV systolic function (ejection fraction).
    Summary · context
    Forty-seven type 2 diabetes patients of South Asian ancestry living in the Netherlands, with or without ischemic heart disease, who were randomly assigned to 26-week treatment with liraglutide (1.8 mg/day) or placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In South Asian adults with type 2 diabetes, liraglutide did not change the E/A ratio compared with placebo.

    In plain wordsIn South Asian adults with type 2 diabetes, liraglutide did not change a heart filling measure compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeRatio of early and late peak filling rate (E/A)
    Study

    n = 47

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg/day · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Liraglutide (n = 22) compared with placebo (n = 25) did not change Edec (+0.2 mL/s2 × 10-3 (-0.3;0.6)), E/A (-0.09 (-0.23;0.05)), E/Ea (+0.1 (-1.2;1.3)) and ejection fraction (0% (-3;2)), but decreased stroke volume (-9 mL (-14;-5)) and increased heart rate (+10 bpm (4;15)).
    2 context sentences
    Summary · context
    Primary endpoints were changes in LV diastolic function (early deceleration peak [Edec], ratio of early and late peak filling rate [E/A], estimated LV filling pressure [E/Ea]) and LV systolic function (ejection fraction).
    Summary · context
    Forty-seven type 2 diabetes patients of South Asian ancestry living in the Netherlands, with or without ischemic heart disease, who were randomly assigned to 26-week treatment with liraglutide (1.8 mg/day) or placebo.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In South Asian adults with type 2 diabetes, liraglutide did not change estimated left ventricular filling pressure compared with placebo.

    In plain wordsIn South Asian adults with type 2 diabetes, liraglutide did not change heart filling pressure compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeEstimated LV filling pressure (E/Ea)
    Study

    n = 47

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg/day · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Liraglutide (n = 22) compared with placebo (n = 25) did not change Edec (+0.2 mL/s2 × 10-3 (-0.3;0.6)), E/A (-0.09 (-0.23;0.05)), E/Ea (+0.1 (-1.2;1.3)) and ejection fraction (0% (-3;2)), but decreased stroke volume (-9 mL (-14;-5)) and increased heart rate (+10 bpm (4;15)).
    2 context sentences
    Summary · context
    Primary endpoints were changes in LV diastolic function (early deceleration peak [Edec], ratio of early and late peak filling rate [E/A], estimated LV filling pressure [E/Ea]) and LV systolic function (ejection fraction).
    Summary · context
    Forty-seven type 2 diabetes patients of South Asian ancestry living in the Netherlands, with or without ischemic heart disease, who were randomly assigned to 26-week treatment with liraglutide (1.8 mg/day) or placebo.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In South Asian adults with type 2 diabetes, liraglutide did not change ejection fraction compared with placebo.

    In plain wordsIn South Asian adults with type 2 diabetes, liraglutide did not change how well the heart pumps compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeEjection fraction
    Study

    n = 47

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg/day · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Liraglutide (n = 22) compared with placebo (n = 25) did not change Edec (+0.2 mL/s2 × 10-3 (-0.3;0.6)), E/A (-0.09 (-0.23;0.05)), E/Ea (+0.1 (-1.2;1.3)) and ejection fraction (0% (-3;2)), but decreased stroke volume (-9 mL (-14;-5)) and increased heart rate (+10 bpm (4;15)).
    2 context sentences
    Summary · context
    Primary endpoints were changes in LV diastolic function (early deceleration peak [Edec], ratio of early and late peak filling rate [E/A], estimated LV filling pressure [E/Ea]) and LV systolic function (ejection fraction).
    Summary · context
    Forty-seven type 2 diabetes patients of South Asian ancestry living in the Netherlands, with or without ischemic heart disease, who were randomly assigned to 26-week treatment with liraglutide (1.8 mg/day) or placebo.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In South Asian adults with type 2 diabetes, aortic pulse wave velocity was unaltered by liraglutide compared with placebo.

    In plain wordsIn South Asian adults with type 2 diabetes, liraglutide did not change aortic stiffness compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeAortic pulse wave velocity (PWV)
    Study

    n = 47

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    1.8 mg/day · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Aortic PWV (+0.5 m/s (-0.6;1.6)), myocardial triglyceride content (+0.21% (-0.09;0.51)), and ECV (-0.2% (-1.4;1.0)) were unaltered.
    2 context sentences
    Summary · context
    Secondary endpoints were changes in aortic stiffness (aortic pulse wave velocity [PWV]), myocardial steatosis (myocardial triglyceride content), and diffuse fibrosis (extracellular volume [ECV]).
    Summary · context
    Forty-seven type 2 diabetes patients of South Asian ancestry living in the Netherlands, with or without ischemic heart disease, who were randomly assigned to 26-week treatment with liraglutide (1.8 mg/day) or placebo.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In South Asian adults with type 2 diabetes, myocardial triglyceride content was unaltered by liraglutide compared with placebo.

    In plain wordsIn South Asian adults with type 2 diabetes, liraglutide did not change fat in the heart muscle compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeMyocardial triglyceride content
    Study

    n = 47

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg/day · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Aortic PWV (+0.5 m/s (-0.6;1.6)), myocardial triglyceride content (+0.21% (-0.09;0.51)), and ECV (-0.2% (-1.4;1.0)) were unaltered.
    2 context sentences
    Summary · context
    Secondary endpoints were changes in aortic stiffness (aortic pulse wave velocity [PWV]), myocardial steatosis (myocardial triglyceride content), and diffuse fibrosis (extracellular volume [ECV]).
    Summary · context
    Forty-seven type 2 diabetes patients of South Asian ancestry living in the Netherlands, with or without ischemic heart disease, who were randomly assigned to 26-week treatment with liraglutide (1.8 mg/day) or placebo.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In South Asian adults with type 2 diabetes, myocardial extracellular volume was unaltered by liraglutide compared with placebo.

    In plain wordsIn South Asian adults with type 2 diabetes, liraglutide did not change a heart scarring measure compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeExtracellular volume (ECV)
    Study

    n = 47

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg/day · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Aortic PWV (+0.5 m/s (-0.6;1.6)), myocardial triglyceride content (+0.21% (-0.09;0.51)), and ECV (-0.2% (-1.4;1.0)) were unaltered.
    2 context sentences
    Summary · context
    Secondary endpoints were changes in aortic stiffness (aortic pulse wave velocity [PWV]), myocardial steatosis (myocardial triglyceride content), and diffuse fibrosis (extracellular volume [ECV]).
    Summary · context
    Forty-seven type 2 diabetes patients of South Asian ancestry living in the Netherlands, with or without ischemic heart disease, who were randomly assigned to 26-week treatment with liraglutide (1.8 mg/day) or placebo.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In South Asian adults with type 2 diabetes, liraglutide decreased stroke volume compared with placebo.

    In plain wordsIn South Asian adults with type 2 diabetes, liraglutide lowered stroke volume of the heart compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseStroke volume
    Study

    n = 47

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg/day · 26 weeksAs given in this study (human).

    Measurements

    Stroke volume difference
    −9 mL
    liraglutide vs placebo

    Source sentences

    Summary
    Liraglutide (n = 22) compared with placebo (n = 25) did not change Edec (+0.2 mL/s2 × 10-3 (-0.3;0.6)), E/A (-0.09 (-0.23;0.05)), E/Ea (+0.1 (-1.2;1.3)) and ejection fraction (0% (-3;2)), but decreased stroke volume (-9 mL (-14;-5)) and increased heart rate (+10 bpm (4;15)).
    1 context sentence
    Summary · context
    Forty-seven type 2 diabetes patients of South Asian ancestry living in the Netherlands, with or without ischemic heart disease, who were randomly assigned to 26-week treatment with liraglutide (1.8 mg/day) or placebo.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In South Asian adults with type 2 diabetes, liraglutide increased heart rate compared with placebo.

    In plain wordsIn South Asian adults with type 2 diabetes, liraglutide raised heart rate compared with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseHeart rate
    Study

    n = 47

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg/day · 26 weeksAs given in this study (human).

    Measurements

    Heart rate difference
    10 bpm
    liraglutide vs placebo

    Source sentences

    Summary
    Liraglutide (n = 22) compared with placebo (n = 25) did not change Edec (+0.2 mL/s2 × 10-3 (-0.3;0.6)), E/A (-0.09 (-0.23;0.05)), E/Ea (+0.1 (-1.2;1.3)) and ejection fraction (0% (-3;2)), but decreased stroke volume (-9 mL (-14;-5)) and increased heart rate (+10 bpm (4;15)).
    1 context sentence
    Summary · context
    Forty-seven type 2 diabetes patients of South Asian ancestry living in the Netherlands, with or without ischemic heart disease, who were randomly assigned to 26-week treatment with liraglutide (1.8 mg/day) or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.